Answers are grounded in this paper and cite their sources.
Periodontitis is a biofilm-mediated, host-modulated inflammatory disease in which dysbiotic subgingival communities and a susceptible host response reinforce one another. This model challenges the assumption that detecting canonical periodontal pathogens is sufficient to diagnose active disease or select systemic antibiotics. This focused narrative review examines whether microbiological testing should guide adjunctive systemic antibiotic use during nonsurgical periodontal therapy. European Federation of Periodontology guidelines recommend against routine systemic antibiotics, prioritizing high-quality subgingival instrumentation and risk-factor control, given the adverse-event, ecological, and antimicrobial-resistance costs. Evidence syntheses show modest average benefits for some adjunctive regimens, most consistently amoxicillin plus metronidazole, but baseline detection of a specific organism has not been shown to identify patients who preferentially benefit. Culture with susceptibility testing, targeted molecular assays, 16S rRNA sequencing, shotgun metagenomics, and ex vivo biofilm-response assays answer different questions and have distinct limitations. Microbiological testing is therefore best regarded as a decision-contingent adjunct rather than a routine gatekeeper, useful when an antibiotic is already being considered for an exceptional indication and the result can alter management or avoid unnecessary exposure. Future trials should compare complete test-guided strategies with guideline-based clinical selection, evaluating patient-centered outcomes, adverse events, ecological effects, antibiotic exposure, resistance, and cost-effectiveness.
No takes yet. Share an insight, caveat, or question.
Al-Hattali et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: